Evidence map›Paper›PMID 36810540›Full record

ArticleDiseases (Basel, Switzerland)2023

Non-Small-Cell Lung Cancer Immunotherapy and Sleep Characteristics: The Crossroad for Optimal Survival.

Paul Zarogoulidis, Dimitrios Petridis, Christoforos Kosmidis, Konstantinos Sapalidis, Lila Nena, Dimitris Matthaios, Vasilis Papadopoulos, Eleni Isidora Perdikouri, Konstantinos Porpodis, Paschalis Kakavelas and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diseases (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Sleep and Cancer.Cancers · 2025
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 1 country.

Paul ZarogoulidisPulmonary Department, General Clinic Euromedica Private Hospital, 68100 Thessaloniki, Greece.ORCID 0000-0001-5119-2207
Dimitrios PetridisDepartment of Food Technology, School of Food Technology and Nutrition, Alexander Technological Educational Institute, 64556 Thessaloniki, Greece.
Christoforos Kosmidis3rd Surgery Department, AHEPA University Hospital, Aristotle University of Thessaloniki, 54646 Thessaloniki, Greece.
Konstantinos Sapalidis3rd Surgery Department, AHEPA University Hospital, Aristotle University of Thessaloniki, 54646 Thessaloniki, Greece.
Lila NenaLaboratory of Social Medicine, Medical School, Democritus University of Thrace, 68100 Alexandroupolis, Greece.
Dimitris MatthaiosOncology Department, General Hospital of Rhodes, 85100 Rhodes, Greece.
Vasilis PapadopoulosOncology Department, University Hospital of Larissa, 77543 Thessali, Greece.
Eleni Isidora PerdikouriOncology Department, General Hospital of Volos, 34456 Volos, Greece.
Konstantinos PorpodisPulmonary Department, "G. Papanikolaou" General Hospital, Aristotle University of Thessaloniki, 54768 Thessaloniki, Greece.ORCID 0000-0001-7215-2191
Paschalis KakavelasIntensive Care Unit, General Clinic Euromedica, Private Hospital, 54667 Thessaloniki, Greece.
Paschalis SteiropoulosDepartment of Respiratory Medicine, Medical School, Democritus University of Thrace, 68100 Alexandroupolis, Greece.
Aristotle University of Thessaloniki · GRDemocritus University of Thrace · GRAgios Pavlos General Hospital · GRAlexander Technological Educational Institute of Thessaloniki · GREuromedica · GRGeneral Hospital of Rhodes · GRUniversity Hospital of Larissa · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionNon-small-cell lung cancer is still diagnosed at an inoperable stage and systematic treatment is the only option. Immunotherapy is currently considered to be the tip of the arrow as the first-line treatment for patients with a programmed death-ligand 1 ≥ 50. Sleep is known to be an essential part of our everyday life. PATIENTS AND

methodsWe investigated, upon diagnosis and after nine months, 49 non-small-cell lung cancer patients undergoing immunotherapy treatment with nivolumab and pemprolisumab. A polysomnographic examination was conducted. Moreover, the patients completed the Epworth Sleepiness Scale (ESS), the Pittsburgh Sleep Quality Index (PSQI), the Fatigue Severity Scale (FSS) and the Medical Research Council (MRC) dyspnea scale.

resultsTukey mean-difference plots, summary statistics, and the results of paired

conclusionUpon diagnosis, lung cancer patients have sleep disorders such as anxiety, early morning wakening, late sleep onset, prolonged nocturnal waking periods, daytime sleepiness, and unrefreshing sleep. However, these symptoms tend to improve very quickly for patients with a PD-L1 expression ≥80, because disease status improves also very quickly within the first 4 months of treatment.

Indexed as

cancerimmunotherapyinsomnianon-small-cell lung cancerpolysomnographysleep medicine

Identifiers

PMID36810540
PMCPMC9944906
OpenAlexW4319005180

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.